StudyFinder
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
RECRUITING
18 years and over
Inclusion Criteria:
* Adults aged greater than or equal to (\>=) 18 years on the day of signing the informed consent form.
* Confirmed diagnosis of SCD of any genotype.
* Experienced 1 to 12 VOCs requiring a visit to a medical facility and treatment with parenteral opioids or a parenteral nonsteroidal anti-inflammatory drug within the 12 months before Screening.
* HU Regimen:
* a. On stable and well-tolerated Hydroxyurea (HU) regimen for at least 30 days before Screening.
* or
* b. HU was discontinued or refused (eg, due to concern of side effects or lack of effect).
Exclusion Criteria:
* Absolute neutrophil count less than (\<) 2.5 ×10\^9 cells/Litre at Screening or Baseline (Week 1 Day 1).
* If on SCD preventive medication, dose is not stable in the 30 days before Screening.BIOLOGICAL: Anumigilimab, DRUG: Placebo
Sickle Cell Disease
Anemia, Genetic Disorder, Vaso-occlusive Crises
Trial Registration Coordinator - clinicaltrials@cslbehring.com
NCT07224360